Insights

Innovative Drug Platform UroGen Pharma's proprietary RTGel reverse-thermal hydrogel technology offers a versatile and sustained-release drug delivery solution with potential applications across various unmet medical needs in urology and oncology, providing opportunities for licensing, partnerships, and co-development projects.

Expanding Pipeline With multiple candidates in different clinical stages, including pre-clinical to Phase 3, UroGen presents a robust pipeline geared toward addressing specialty cancers and urologic diseases, which can attract investment or partnership interest for joint clinical development or commercialization.

Strategic Collaborations UroGen’s active partnerships, like its recent collaboration with Code District LLC, indicate openness to digital transformation and innovative solutions, opening doors for technology vendors, data analytics firms, or digital platform providers seeking strategic alliances.

Funding & Financial Growth The planned $250 million term loan and recent funding milestones suggest strong financial backing and growth potential, presenting opportunities for sales of medical devices, research tools, or clinical services to support their development and expansion strategies.

Market Visibility Participation in high-profile industry conferences and ongoing communication strategies provide avenues for outreach, enabling sales teams to connect directly with decision-makers and key stakeholders involved in biopharma investments and therapeutic licensing opportunities.

UroGen Pharma Tech Stack

UroGen Pharma uses 8 technology products and services including SAS, GDPR, Underscore.js, and more. Explore UroGen Pharma's tech stack below.

  • SAS
    Business Intelligence
  • GDPR
    Certificates
  • Underscore.js
    Javascript Libraries
  • Netlify Forms
    Online Form Builders
  • Netlify
    Platform As A Service
  • WhatsApp
    Social Sharing
  • Google Search Console
    Web Analytics
  • Apache
    Web Servers

Media & News

UroGen Pharma's Email Address Formats

UroGen Pharma uses at least 1 format(s):
UroGen Pharma Email FormatsExamplePercentage
First.Last@urogen.comJohn.Doe@urogen.com
91%
FirstL@urogen.comJohnD@urogen.com
8%
First.Middle@urogen.comJohn.Michael@urogen.com
1%

Frequently Asked Questions

Where is UroGen Pharma's headquarters located?

Minus sign iconPlus sign icon
UroGen Pharma's main headquarters is located at 400 Alexander Park Drive 4th Floor Princeton, New Jersey United States. The company has employees across 4 continents, including North AmericaAsiaEurope.

What is UroGen Pharma's official website and social media links?

Minus sign iconPlus sign icon
UroGen Pharma's official website is urogen.com and has social profiles on LinkedInCrunchbase.

What is UroGen Pharma's SIC code NAICS code?

Minus sign iconPlus sign icon
UroGen Pharma's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does UroGen Pharma have currently?

Minus sign iconPlus sign icon
As of May 2026, UroGen Pharma has approximately 319 employees across 4 continents, including North AmericaAsiaEurope. Key team members include Ceo: L. B.Chief Commercial Officer: D. L.Chief Financial Officer: C. D.. Explore UroGen Pharma's employee directory with LeadIQ.

What industry does UroGen Pharma belong to?

Minus sign iconPlus sign icon
UroGen Pharma operates in the Biotechnology Research industry.

What technology does UroGen Pharma use?

Minus sign iconPlus sign icon
UroGen Pharma's tech stack includes SASGDPRUnderscore.jsNetlify FormsNetlifyWhatsAppGoogle Search ConsoleApache.

What is UroGen Pharma's email format?

Minus sign iconPlus sign icon
UroGen Pharma's email format typically follows the pattern of First.Last@urogen.com. Find more UroGen Pharma email formats with LeadIQ.

When was UroGen Pharma founded?

Minus sign iconPlus sign icon
UroGen Pharma was founded in 2004.

UroGen Pharma

Biotechnology ResearchNew Jersey, United States201-500 Employees

UroGen Pharma is a biotech company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. Our vision is grounded in our RTGel® drug delivery technology, our promising pipeline, and a collaborative drive for bold results. 

Our existing technology: the RTGel drug delivery technology has the potential to be applied to a variety of unmet medical needs. RTGel reverse-thermal hydrogel is liquid at lower temperatures and converts to gel form at body temperature, offering the opportunity to make local therapy a more effective treatment.

Our promising pipeline: Ranging from pre-clinical to Phase 3, we currently have multiple candidates in our pipeline, which are furthering the study of potential treatment advances in urology, uro-oncology, and immunology.

Our collaborative drive: We are part of a broad ecosystem of partners who are seeking to improve patient care; these connections are vital to our commitment to offer new pathways and advance solutions. We are continually evaluating new partnership opportunities.

Section iconCompany Overview

Headquarters
400 Alexander Park Drive 4th Floor Princeton, New Jersey United States
Website
urogen.com
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2004
Employees
201-500

Section iconFunding & Financials

  • $50M$100M

    UroGen Pharma's revenue is estimated to be in the range of $50M$100M

Section iconFunding & Financials

  • $50M$100M

    UroGen Pharma's revenue is estimated to be in the range of $50M$100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.